ICM
PTGX icon

ISZO Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

ISZO Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-93,883
Closed -$4.21M – 9
2021
Q2 		$4.21M Buy
+93,883
New +$3.1M 1.53% 7

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ISZO Capital Management's PTGX Position: Q3 2021 in Review

ISZO Capital Management sold out of Protagonist Therapeutics (PTGX) in Q3 2021, closing a stake of 93,883 shares — an estimated $4.21M sold.

ISZO Capital Management first reported a position in PTGX in Q2 2021 and held it in 1 quarter. The position peaked at $4.21M in Q2 2021. 132 funds tracked by Wall St. Rank hold PTGX as of Q3 2021.

  • ISZO Capital Management reported no remaining Protagonist Therapeutics position as of Q3 2021 after selling out during the quarter.
  • ISZO Capital Management sold 93,883 Protagonist Therapeutics shares in Q3 2021, an estimated $4.21M.
  • ISZO Capital Management first reported a position in Protagonist Therapeutics in Q2 2021 and held it in 1 quarter.
  • ISZO Capital Management's Protagonist Therapeutics position peaked at $4.21M in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2021.

Based on ISZO Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.